OncoZenge AB

OncoZenge AB TEMP's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, OncoZenge AB TEMP has 13.00M shares outstanding.

As of June 30, 2026, OncoZenge AB TEMP maintains a current ratio of 0.51, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.50, indicating elevated leverage, while an interest coverage ratio of -34.59 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, OncoZenge AB TEMP posted a negative return on equity (ROE) of -255.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -131.13, reflecting losses generated across the asset base.

As of the close on October 2, 2026, OncoZenge AB TEMP's stock has declined approximately 67.21% over the past 52 weeks.

Over the twelve months ended June 30, 2026, OncoZenge AB TEMP generated 5.84M in revenue and converted that into -25.29M in net income, yielding earnings per share of -2.12. EBITDA reached -24.60M, while operating income came in at -24.60M.

As of June 30, 2026, OncoZenge AB TEMP holds 749,000.00 in cash and equivalents against 7.50M in total debt, resulting in a net debt position of 6.75M. Total book value stands at 9.80M, with working capital of -4.65M providing operational flexibility.

OncoZenge AB TEMP produced -20.65M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -421.16 and net profit margin of -433.08 provide insight into operational efficiency.